When do biologic drug patents expire and when will biosimilars launch?

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	January 15, 1974	⤷ Start Trial	2027-03-16
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	December 27, 1984	⤷ Start Trial	2027-03-16
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	February 15, 1985	⤷ Start Trial	2027-03-16
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	February 16, 1990	⤷ Start Trial	2027-03-16
Bel-mar Laboratories, Inc.	CHORIONIC GONADOTROPIN	chorionic gonadotropin	Injection	017054	March 26, 1974	⤷ Start Trial	2027-03-16
Fresenius Kabi Usa, Llc	CHORIONIC GONADOTROPIN	chorionic gonadotropin	For Injection	017067	March 05, 1973	⤷ Start Trial	2027-03-16
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Title:	Dosing regimens for neural stem cell proliferating agents and differentiating agents for the treatment of neurological disorders
Abstract:	Effective dosing regimens for neural stem cell proliferating and differentiating agents, kits comprising effective dosing regimens for neural stem cell proliferating and differentiating agents, and uses thereof are provided herein. Such kits and methods can be utilized acutely or chronically to treat a neurodegenerative disease or condition. Furthermore, the compositions and methods can be used continuously or intermittently in various dosing regimens.
Inventor(s):	Weiss; Samuel (Calgary, CA), Gregg; Christopher (Cambridge, MA)
Assignee:	Stem Cell Therapeutics Corp. (Calgary, CA)
Application Number:	11/687,302
Patent Claims:	1. A method of treating or ameliorating a neurodegenerative disease or condition in a mammal comprising administering to the mammal an effective amount of human chorionic gonadotropin (hCG) during a first treatment period lasting at least three days and administering to the mammal an effective amount of erythropoietin (EPO) during a second treatment period lasting at least three days, wherein the neurodegenerative disease or condition is a stroke, and wherein the second treatment period starts after the end of the first treatment period. 2. The method of claim 1, wherein the hCG is administered systemically.

Claims for Patent: 8,143,220